Lyrica

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 17:03, July 17, 2018 by 77.111.247.9 (talk) (create and begin to populate)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Lyrica is the brand name for (pregabalin) which is its active ingredient. It is used to treat Fibromyalgia, diabetic nerve pain, pain after shingles, spinal cord injure nerve pain, and partial onset seizures in adults (an add-on treatment) with epilepsy.

Side Effects[edit | edit source]

More commonly reported ones are:


More commonly reported ones in children are:


Less commonly reported ones are:


Generic legal battle[edit | edit source]

  • Mar 2012, Pfizer blocked Israel-based Teva Pharmaceutical Industries and other manufacturers from selling generic versions of Lyrica.[1]
  • 2014, Pfizer Inc., the maker of Lyrica, successfully blocked the marketing of Pregabalin generics until December of 2018 arguing that the generics should not be marketed and made available until after their patent ran out.[4] Warner-Lamber, (a subsidieary of Pfizer), "still holds a “second medical use” patent for the use of pregabalin in the treatment of peripheral and central neuropathic pain, which expires in July 2017. A second medical use patent is one that relates to a new medical use for a known compound."[5][6]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]